Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Theratechnologies Inc
T.TH
Alternate Symbol(s):
THTX
Healthcare
Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs...
in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (TSX:TH)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
(78)
•••
jfm1330
X
View Profile
View Bullboard History
Comment by
jfm1330
on May 25, 2024 12:20pm
RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
I don't know if they can attract a partner. That being said, a big pharma like Bristol Myers Squibb now has this expertise. They bought RayzeBio for 4.1 B$ and their main drug candidate is 225 Ac
...more
(133)
•••
Trogarzon
X
View Profile
View Bullboard History
Comment by
Trogarzon
on May 25, 2024 11:23am
RE:RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Just get upfront to pay back the Shylock and get double digit on whatever comes out of this drug. That simple.
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource
posted Sep 19, 2024 9:00am by
Northstar Gold Corp.
-
|
The MOU grants Hunan Nonferrous the opportunity to explore and develop a near-surface NI43-101 gold mineral resource at Northstar’s 100%-owned Miller Copper-Gold Property, located 18 kilometers southeast of Kirkland Lake, Ontario. This will be achieved by diamond drilling up to 10,000 meters, allowing Hunan Nonferrous to earn a negotiated interest in the resultant NI43-101 gold resource. ...read more
(86)
•••
Mannequin
X
View Profile
View Bullboard History
Comment by
Mannequin
on May 25, 2024 10:48am
RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
As they have FDA Fast Track, do you think there is any leniency at the FDA for amending the trial (with a partner who has experience) to add Ga68 without having to start the trial from scratch?
...more
(78)
•••
jfm1330
X
View Profile
View Bullboard History
Comment by
jfm1330
on May 25, 2024 9:08am
RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
The strong scientific rationale was there from the beginning. A company with real financial means and stong scientific people would have integrated it in their clinical protocol from the beginning. I
...more
(86)
•••
Mannequin
X
View Profile
View Bullboard History
Comment by
Mannequin
on May 25, 2024 3:56am
RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
The cannot start a Ga68 trial without evidence. Coupling a clinical trial with Ga-68 (Gallium-68) involves using this radioisotope in conjunction with a PET scan to enhance the imaging and diagnostic
...more
(78)
•••
jfm1330
X
View Profile
View Bullboard History
Comment by
jfm1330
on May 24, 2024 7:49pm
RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
If all they have on humans is stable disease, even on half of the patients, it will be hard to attract a partner, again, because it means the long and costly road to approval and they have nothing
...more
(51)
•••
Qwerty54321
X
View Profile
View Bullboard History
Comment by
Qwerty54321
on May 24, 2024 5:21pm
RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Certainly stable disease is a great thing for individual patients but it is how you develop a clinical trial program and where the drug ends up fitting into the clinic in terms of other drugs on the
...more
(79)
•••
SPCEO1
X
View Profile
View Bullboard History
Comment by
SPCEO1
on May 24, 2024 4:28pm
RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Thanks JFM! You doindeed know of what you speak - may you go from stability to restored health!
(2)
•••
ANALIAS00
X
View Profile
View Bullboard History
Comment by
ANALIAS00
on May 24, 2024 3:28pm
RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Thank you....for everything !!
(78)
•••
jfm1330
X
View Profile
View Bullboard History
Comment by
jfm1330
on May 24, 2024 2:44pm
RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Hey, I wrote something just as you were posting this. Some telepathy I guess!!!
(78)
•••
jfm1330
X
View Profile
View Bullboard History
Comment by
jfm1330
on May 24, 2024 2:43pm
RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Stable disease for many years is a very good outcome on advanced patients. Take my word for that. That being said, approval through progression free survival (PFS) takes much longere than through
...more
(79)
•••
SPCEO1
X
View Profile
View Bullboard History
Comment by
SPCEO1
on May 24, 2024 2:15pm
RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
JFM - hoping you are still doing well and that you are up to offering your thoughts on the latest press release.
(51)
•••
Qwerty54321
X
View Profile
View Bullboard History
Comment by
Qwerty54321
on May 24, 2024 12:36pm
RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Analias, I don't really think these result are a strong indicator of either the path this drug is going to take through clinical trials from this point onwards or even the utility of the drug. I
...more
(51)
•••
Qwerty54321
X
View Profile
View Bullboard History
Comment by
Qwerty54321
on May 24, 2024 12:25pm
RE:RE:RE:RE:RE:RE:New Press Release - Theratechnologies' Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
So my initial thoughts revolve around the MOA too. Both positive and negative or should I say still full of questions. You are right about the multi MOA coming from the preclinical work but I don
...more
Prev
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Mining Player Sells Off Promising Project for Millions – Here's Where the Cash is Headed
EnviroGold Global Announces Appointment of Chief Operating Officer